IGM Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
07/03/2025 17:09
IGM Biosciences Inc IGMS.OQ reported a quarterly adjusted loss of 61 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.01. The mean expectation of ten analysts for the quarter was for a loss of 74 cents per share. Wall Street expected results to range from -93 cents to -57 cents per share. Revenue fell 36.7% to $412.00 thousand from a year ago; analysts expected $393.75 thousand. IGM Biosciences Inc's reported EPS for the quarter was a loss of 61 cents. The company reported a quarterly loss of $36.65 million. IGM Biosciences Inc shares had fallen by 77.1% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 5.1% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 9 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold" Wall Street's median 12-month price target for IGM Biosciences Inc is $2.00 This summary was machine generated from LSEG data March 7 at 05:09 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.74 | -0.61 | Beat |
| Sep. 30 2024 | -0.80 | -1.01 | Missed |
| Jun. 30 2024 | -0.04 | -0.79 | Missed |
| Mar. 31 2024 | -0.83 | -0.83 | Met |
Recent news on IGM Biosciences
See all newsU.S. STOCKS ON THE MOVE-Energy stocks, Apple, Vertex
U.S. STOCKS ON THE MOVE-Snap, Solventum, GlobalFoundries
IGM Biosciences rises on buyout deal with Concentra Biosciences
Brief: Igm Biosciences Enters Into Agreement To Be Acquired By Concentra Biosciences For $1.247 In Cash Per Share Plus A Contingent Value Right
IGM Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary